SHANGHAI, June 5, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for...
Read More Details
Finally We wish PressBee provided you with enough information of ( YolTech Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for YOLT-101, an In Vivo Base Editing Therapy to Treat Heterozygous Familial Hypercholesterolemia (HeFH) )
Also on site :
- Hoda Kotb Reveals Who Should Be Jenna Bush Hager's 'Today' Co-host
- Tim McGraw's Daughter Audrey Debuts Duet with Son of Country Icon: 'It's a Special One'
- Beloved Rock Star, 76, Reveals Affair With Best Friend's Wife Led to Two Suicide Attempts and a Coma